melior discovery

About Us
Our Pipeline
Our Platform
Partnering with Us
Contact Us

Click here for the MLR-1023 non-confidential brochure          

melior melior discovery

Our Pipeline MLR-1130 (atopic dermatitis)

Melior Pharmaceuticals pipeline

Click chart for a larger view.

MLR-1130 is Melior's therapeutic candidate for atopic dermatitis. Originally evaluated for the treatment of Alzheimer's disease, MLR-1130 proved safe through Phase III clinical trials but was discontinued due to lack of efficacy in the original indication. Melior has repositioned the drug and is now exploring its potential utility as a small molecule candidate for the treatment of atopic dermatitis.

Atopic dermatitis is a chronic, eczematous skin disease that often begins in childhood and continues throughout adulthood. In the United States, atopic dermatitis affects an estimated 7 to 17% of children, and a small percentage of those will continue to show symptoms of the disease into adulthood.

There are several existing therapies for the treatment of eczema/atopic dermatitis, including (1) topical steroids, which can lead to thinning of the skin; (2) calcineurin inhibitors (i.e., Protopic or Elidel) that have been linked to the formation of skin cancers; and (3) non-prescription creams (e.g., Atopiclair) that have soothing properties but are not pharmacologically active. MLR-1130 is a topical non-steroidal, non-calcineurin inhibitor anti-inflammatory agent that is effective both therapeutically and prophylactically in validated animal models of dermal inflammation.

All Melior drug candidates have demonstrated the effectiveness of the theraTRACE® drug repositioning platform, which allows the Company to rapidly and systematically evaluate a compound's efficacy across a large number of high quality disease models predictive of utility in multiple therapeutic areas.

In building a robust portfolio of drug candidates, Melior is substantially increasing the likelihood for clinical success in the development process by focusing on candidates that have previously been shown to safe in phase II or phase III clinical trials, are orally bioavailable and possess ideal physico-chemical or "drug-like" properties. Melior's current product portfolio consists of drugs with significantly reduced development risk based on these key attributes. Melior continues to identify additional product candidates that meet the above criteria as part of its effort to build a promising pipeline based on products with potential for new indications.

If you are interested in learning more about MLR-1130, please contact to start the conversation.

Back to top of page